Dr. Reddy's Laboratories(NYSE) RDY

Dr. Reddy's Laboratories Limited is a global pharmaceutical company based in Hyderabad, India, specializing in the manufacturing and marketing of a wide range of pharmaceutical products. The company operates through various segments, including Global Generics, Pharmaceutical Services and Active Ingredients, Proprietary Products, and Others, addressing diverse therapeutic areas.

Products and Services

• Manufactures prescription and over-the-counter pharmaceutical products
• Produces active pharmaceutical ingredients and chemical intermediates
• Researches unique pharmaceutical formulations and oncology treatments

Growth Outlook

• Revenue increased to INR 81.18 billion in Q1 2026, up from INR 76.33 billion in Q4 2025
• Net income rose to INR 4.46 billion in Q1 2026, reflecting strong operational performance
• Continued investment in R&D, with INR 5.8 billion allocated in Q1 2026

Financial Highlights

• Trailing twelve-month revenue of INR 327.5 billion, showcasing consistent growth
• Net profit margin of 9.99% indicates effective cost management
• Operating cash flow of INR 15.44 billion in Q4 2026 supports financial stability

Dr. Reddy's Laboratories Limited has established itself as a key player in the pharmaceutical industry, with a strong focus on innovation and quality. The company's diverse product offerings and commitment to research and development position it well for future growth. Recent financial performance highlights a robust revenue trajectory and effective cost management, making it an attractive option for potential investors. The ongoing investments in R&D further enhance the company's prospects in a competitive market.